Equities

Ifa Systems AG

IS8:HAM

Ifa Systems AG

Actions
  • Price (EUR)2.50
  • Today's Change0.00 / 0.00%
  • Shares traded400.00
  • 1 Year change-16.67%
  • Beta0.8991
Data delayed at least 15 minutes, as of Jul 05 2024 07:16 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ifa Systems AG is a Germany-based company that provides information technology (IT) solutions and components for eye care specialists. It develops, distributes and installs software, medicine information systems for clinics and medical practitioners, particularly for ophthalmic surgeons, ophthalmologists, technicians, nurses, as well as eye care managers and administrators. The Company’s main product is an electronic patient file, which includes all information about the examination and treatment, based on gathered data from more than 480 ophthalmological devices. It also provides solutions that enable the capture, analysis and archiving of images, documents and data, as well as scheduling and workflow management. In addition, it offers consulting, system integration, training, and hotline services. The Company serves clients in more than 30 countries worldwide.

  • Revenue in EUR (TTM)5.88m
  • Net income in EUR-570.00k
  • Incorporated2002
  • Employees51.00
  • Location
    Ifa Systems AGAugustinusstr. 11bFRECHEN 50226GermanyDEU
  • Phone+49 2 234933670
  • Fax+49 22 349336730
  • Websitehttps://www.ifasystems.de/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Glycorex Transplantation AB (publ)2.73m-2.60m5.72m15.00--1.68--2.10-0.40-0.400.41970.54850.39780.72834.601,347,652.00-37.91-11.30-47.48-13.1784.7991.60-95.30-33.241.20-118.900.2046---17.04-2.15-254.06---0.5593--
Codelab Capital AS-8.75bn-8.75bn5.80m200.00--0.4739----------0.633----------------------------0.00--------------
iZafe Group AB440.59k-2.89m5.81m7.00--3.03--13.19-0.133-0.1330.02010.07910.1091.242.46714,857.10-71.38-52.17-82.09-69.40-10.99---655.02-487.500.6947--0.1174--149.93-24.79-36.76---41.66--
ProstaLund AB1.77m-1.63m5.97m6.00--0.798--3.37-0.2436-0.24360.26380.6340.39120.432511.14---36.07-29.14-40.73-35.0171.0575.26-92.21-68.941.90-126.960.0255--27.5410.36-53.27--20.35--
Myhealthchecked PLC12.95m-187.63k6.14m10.00--0.597581.260.4738-0.0031-0.00310.21110.16740.886310.984.441,097,700.00-1.28-7.24-1.81-10.3918.6622.82-1.45-5.132.46--0.003---50.81368.95-110.48---2.00--
Kontigo Care AB2.59m68.24k6.21m10.0067.051.9715.522.390.03280.03281.171.120.6807--7.69--1.79-0.42142.55-0.619568.8466.312.63-0.5205--4.000.093--1.8016.95-92.68--44.94--
Immunovia AB (publ)106.71k-22.96m6.70m11.00--1.74--62.77-6.06-6.060.02760.96480.007558.2314.96110,181.80-160.93-41.33-194.89-44.24-5,523.76-7,553.76-21,512.13-20,879.292.03--0.1675--37.5536.48-84.09---50.93--
SciBase Holding AB (publ)2.13m-4.89m6.78m26.00--2.01--3.19-0.5255-0.52550.22370.24570.30040.78634.33894,592.60-69.07-68.63-90.03-87.7769.2861.28-229.94-300.201.78--0.00--29.9327.50-28.75--5.15--
ifa systems AG5.88m-570.00k6.88m51.00--0.99926.751.17-0.2073-0.20732.142.500.557611.876.94115,196.10-5.413.26-6.454.5888.2491.21-9.706.452.37--0.000.00-8.47-2.33-162.50------
BBS-Bioactive Bone Substitutes Oyj0.00-3.48m7.02m----1.31-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
AtomTrace as-3.98bn-3.98bn7.14m-----------------------------80.37---185.01---53.82---184.79--------15,237.41130.45107.12------
Bio-Works Technologies AB3.86m-5.00m7.69m38.00--1.98--1.99-1.58-1.581.221.130.5711.825.831,155,158.00-73.91-49.14-101.72-57.9061.1069.88-129.44-168.302.79--0.00--6.2346.24-26.41--1.95--
ScandiDos AB5.32m-1.29m7.78m34.00--1.60--1.46-0.3211-0.32111.320.9710.78530.55526.07---19.03-12.60-33.80-21.9378.6982.13-24.24-15.370.9148-11.58-----1.824.36-60.62---19.29--
Rua Life Sciences PLC2.21m-2.21m8.06m40.00--0.6535--3.65-0.0843-0.08430.08430.16830.32933.264.8046,725.00-32.95-25.97-36.33-28.2681.97---100.05-110.532.40-61.710.1065--34.0940.083.10--94.82--
PMD Device Solutions AB3.49m-3.12m8.33m1.00------2.39-2.06-2.064.14-5.151.58--30.16---141.30------78.66---89.34--0.0373-1.81----------------
Scandinavian Real Heart AB0.00-6.31m8.66m11.00--0.657-----0.4709-0.47090.000.51440.00----0.00-67.22-24.27-78.30-26.81--832.41---6,070.11---701.980.0945---100.00---385.97---25.76--
Data as of Jul 05 2024. Currency figures normalised to Ifa Systems AG's reporting currency: Euro EUR

Institutional shareholders

8.69%Per cent of shares held by top holders
HolderShares% Held
Discover Capital GmbHas of 31 Dec 2023208.55k7.58%
Gay-Lussac Gestion SAas of 31 Dec 202227.46k1.00%
amandea Verm�gensverwaltung AGas of 30 Sep 20233.00k0.11%
Data from 30 Jun 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.